Robert Doebele is an Oncology physician affiliated with The Medical Center of Aurora. OpenAlex indexes 536 publications with 31,913 citations (h-index 74); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 19 Nov 2012.
Clinical trials
- Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
Sponsor: Boundless Bio, Inc.
- Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
Sponsor: Boundless Bio, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44%Serotonin-3 Receptor Antagonist27.4%Ondansetron Hcl100%Part D<11 patientsCorticosteroid16.7%Prednisone100%Part D<11 patientsSensory organs
28.6%Corticosteroid28.6%Dexamethasone100%Part D<11 patientsCancer & immunology
14.3%Kinase inhibitor14.3%Alecensa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2016–2020 per NIH RePORTER. The latest:
- The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.
University of Colorado Denver
FY2020$349,477R01CA193935 - The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.
University of Colorado Denver
FY2019$338,993R01CA193935
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
JTO Clinical and Research Reports
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Sarit Polsky, MD, MPH
The Medical Center of Aurora
Alexandra Sawyer, MD
The Medical Center of Aurora
Tessa Genders, MD, PhD
The Medical Center of Aurora
John Oro, MD
The Medical Center of Aurora
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”